



## Valbiotis continues its expansion in Asia

Creation by the Chinese joint venture of a subsidiary in Singapore  
to access several key Asian markets  
with the goal of becoming the reference in Asia for preventing  
cardiometabolic imbalances through natural, effective and  
clinically tested solutions

**La Rochelle, May 11, 2026** (5:40 PM CEST) – **Valbiotis** (FR0013254851 – ALVAL, PEA/PME eligible), a French laboratory specializing in the design and distribution of scientifically tested dietary supplements to support health at every stage of life, announces the creation by its Chinese joint venture, Hangzhou Valbiotis Life Health Technology, of a subsidiary in Singapore. This presence marks a key first step in the joint venture's expansion in Asia, outside of China and Hong Kong where it is already operational.

The new subsidiary will gradually address several strategic markets in the Asia region, notably Singapore, Vietnam, Indonesia and Japan. The marketing model will rely on both e-commerce channels and traditional distribution networks.

Selection and contracting processes with local distributors have already been initiated. Valbiotis product launches will roll out gradually depending on the timing of regulatory approvals in each country.

### **Commercial launch in China in the second half of 2026**

This new step aligns with the ambition to make the joint venture – owned 49% by Valbiotis and 51% by its partner Aika – the Asian reference for preventing cardiometabolic imbalances through natural, effective and clinically tested solutions.

Commercial operations in the region are still set to start in the second half of 2026, with the joint venture offering Valbiotis products adapted specifically for the Asian market to Chinese consumers. Distribution will be handled by the joint venture's Hong Kong subsidiary through partner cross-border e-commerce (CBEC) platforms, a channel representing about 10% of the Chinese dietary supplements market.

### Shareholder benefit

20% off Valbiotis<sup>PRO</sup>® and Valbiotis<sup>PLUS</sup>® products available from Customer Service ([service-client@valbiotis.com](mailto:service-client@valbiotis.com)) upon proof of ownership of at least 85 shares

Terms and conditions: [click here](#)

## About Valbiotis

Valbiotis is a French laboratory specializing in the creation and distribution of dietary supplements scientifically tested to maintain health at every stage of life. Through an innovative approach combining scientific excellence, plant expertise and a wealth of natural ingredients, Valbiotis offers a new generation of dietary supplements to support cardio-metabolic balance and well-being, and address everyday health issues such as sleep, fatigue, mood management, immunity and vitality. Created at the beginning of 2014 in La Rochelle, France, Valbiotis has forged numerous partnerships with leading academic centers.

Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.

For more information on Valbiotis®, please visit: [www.valbiotis.com](http://www.valbiotis.com)

## Contacts

### Corporate Communication / Valbiotis

**Caroline LAMBERTI**

+ 33 6 77 82 56 88

[caroline.lamberti@valbiotis.com](mailto:caroline.lamberti@valbiotis.com)

### Financial communication / Seitosei.Actifin

**Marianne PY**

+33 6 85 52 76 93

[marianne.py@seitosei-actifin.com](mailto:marianne.py@seitosei-actifin.com)

### Press Relations / LJ Com by JIN

**Valentine MARTIN**

+33 6 32 29 43 82

[v.martin@ljcom.net](mailto:v.martin@ljcom.net)



Name: Valbiotis

ISIN Code: FR0013254851

Ticker Symbol: ALVAL

EnterNext® PEA-PME 150

This press release contains forward-looking statements about Valbiotis' objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections can be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and doubts, including those described in the Valbiotis Universal Registration Document, filed with the French Financial Markets Regulator (AMF) on April 26, 2023, under number D.23-0347, as well as in its Amendment filed with the AMF on December 11, 2023, under number D.23-0347.A01. These documents are available on the Company's website ([www.valbiotis.com](http://www.valbiotis.com)).

This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis' shares or financial securities in any country.